<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00758225</url>
  </required_header>
  <id_info>
    <org_study_id>SN T-II-001-E</org_study_id>
    <nct_id>NCT00758225</nct_id>
  </id_info>
  <brief_title>Long-term Safety, Tolerability and Efficacy of Idebenone in Duchenne Muscular Dystrophy (DELPHI Extension)</brief_title>
  <official_title>A Phase II Open-label Extension Study to Obtain Long-term Safety, Tolerability and Efficacy Data of Idebenone in the Treatment of Duchenne Muscular Dystrophy - Extension to Study SNT-II-001</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Santhera Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Santhera Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The scientific aim of the present extension study is to monitor long-term safety and
      tolerability of idebenone in patients with DMD. Furthermore, the long-term effect on
      respiratory, cardiac and motor functions, and skeletal muscle strength/function will be
      assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measures of safety and tolerability of idebenone: - Nature and frequency of AEs - Laboratory parameters (haematology, biochemistry and urinalysis) - Physical examinations and vital signs - ECGs</measure>
    <time_frame>Month 0, 3, 6, 12, 18, 24, FU</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measures of efficacy of idebenone: - Respiratory Function Testing - Motor Function Measure - Quantitative Muscle Testing - Hand-Held Myometry - Echocardiography and Color Doppler Myocardial Imaging - Cardiac biomarkers</measure>
    <time_frame>Month 0, 6, 12, 18, 24</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>only one arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idebenone</intervention_name>
    <description>Patients ≤ 45 kg: 450 mg/day (1 tablet 3 times a day) Patients &gt; 45 kg: 900 mg/day (2 tablets 3 times a day)</description>
    <arm_group_label>only one arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completion of study SNT-II-001

          -  Body weight ≥ 25 kg

          -  Glucocorticosteroids and ACE-inhibitors are allowed, if on stable dosage within 2
             months prior to inclusion

          -  Eligibility to participate in the present extension study as confirmed by the
             investigator

        Exclusion Criteria:

          -  Safety or tolerability issues arising during the course of SNT-II-001 which in the
             opinion of the investigator preclude further treatment with idebenone

          -  Clinically significant abnormalities of haematology or biochemistry

          -  Abuse of drugs or alcohol

          -  Use of coenzyme Q10 or idebenone within 30 days prior to inclusion

          -  Intake of any investigational drug within 30 days prior to inclusion

          -  Symptomatic heart failure

          -  Previous history of ventricular arrhythmias (other than isolated ventricular
             extrasystole); ventricular arrhythmias presented at baseline

          -  Known individual hypersensitivity to idebenone or to any of the excipients
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof Gunnar Buyse, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2008</study_first_submitted>
  <study_first_submitted_qc>September 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2008</study_first_posted>
  <last_update_submitted>May 30, 2011</last_update_submitted>
  <last_update_submitted_qc>May 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Thomas Meier, PhD / Chief Scientific Officer</name_title>
    <organization>Santhera Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Duchenne Muscular Dystrophy</keyword>
  <keyword>DMD</keyword>
  <keyword>Duchenne</keyword>
  <keyword>Idebenone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Idebenone</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

